DB-1311 + lopinavir + ritonavir

**DB-1311 + lopinavir + ritonavir** is a combination of three drugs: DB-1311, a novel small molecule anticancer agent under early clinical investigation, and the established antiretroviral drugs lopinavir and ritonavir, which are protease inhibitors used primarily in HIV therapy and explored in other viral infections. - **DB-1311** is an investigational anticancer agent from the imidazoacridinone class, designed to act through DNA intercalation and cytotoxicity, currently studied in advanced/metastatic solid tumors[5]. - **Lopinavir + ritonavir** is a fixed-dose combination where lopinavir inhibits the HIV-1 protease, preventing viral polyprotein cleavage, and ritonavir acts mainly as a pharmacokinetic booster by inhibiting CYP3A4, increasing lopinavir plasma concentrations[1][3][7]. There is no evidence in the current search results or standard drug databases of an approved product or trial combining DB-1311 with lopinavir and ritonavir as a single regimen, but listing them together suggests a hypothetical or investigational regimen, potentially for a clinical study where cancer patients with viral co-infection may receive all three drugs.